Cellact Pharma Gmbh

Other

The Brigham and Women's Hospital, Inc.

Purdue Pharma L.p.

Mundipharma International Limited

Nalan Utku

Steven R Gullans

Edgar L Milford

Richard S Blumberg

Yu-Hwa Huang

The present invention pertains to a diagnostic and therapeutic method for assessing whether a patient is susceptible to the treatment of an ester-prodrug. The methods of the invention include the analysis of carboxyelesterase 2 (CES2)-expression in tumor samples as a predictive value for the assessment of treatment success with an ester-prodrug of a chemotherapeutic agent. Alternatively, the invention provides methods involving the analysis of the urinary ratio of the prodrug and the active therapeutic as another predictive value for assessing treatment susceptibility.

Method for the diagnosis of etoposide prodrug treatable cancer

Compounds for treatment of a patient having a tumour that is metastatic and/or that reduces an organ function, wherein the compounds are of the general formula: wherein X is O, NH and S, wherein n is 0, 1 or 2, wherein Rand Rare H, methyl or ethyl, or together form a group CRR, and wherein Rand Rare H, methyl or ethyl.

Analogues of etoposide for the treatment of tumours

The present invention pertains to the use of podophyllotoxin derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.

Etoposide and prodrugs thereof for use in targeting cancer stem cells

Compounds for treatment of a patient having a tumor that is metastatic and/or that reduces an organ function, wherein the compounds are of the general formula: wherein X is O, NH and S, wherein n is 0, 1 or 2, wherein Rand Rare H, methyl or ethyl, or together form a group CRR, and wherein Rand Rare H, methyl or ethyl.

The present invention pertains to the use of podophyllotox in derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.

Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer.

Anti-CEACAM1 recombinant antibodies for cancer therapy

Provided are specific antibodies against T-cell immune response cDNA7 (TIRC7) costimulatory molecule, which are capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs). In particular, high affinity monoclonal and chimeric anti-TIRC7 antibodies are described. Compositions comprising such antibodies and their use for the treatment of immune diseases are provided.

Therapeutic anti-TIRC7 antibodies for use in immune related and other diseases

Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described. Also, the use of said polynucleotide, vector, protein, peptide, polypeptide, or antibody for the preparation of pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided. Furthermore, methods for modulating (antigen-specific) T cell unresponsiveness inducing maintaining or reversing T cell unresponsiveness by inhibiting or stimulating an (unresponsive) T cell through the novel TIRC7 membrane protein are encompassed herein.

T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof

Described are a T cell immune response cDNA 7 (TIRC7) encoding a T-cell transmembrane protein, peptides and polypeptides derived therefrom and antibodies recognizing such (poly)peptides. Peptides, polypeptides and antibodies capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Vectors comprising polynucelotides encoding such polypeptides and peptides, host cells transformed therewith, and their use in the production of such, peptides or polypeptides are also described.

T-cell membrane protein (TIRC7) and peptides derived therefrom

A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises particular therapeutic and preventive treatment regimens for the administration of a T-cell immune response cDNA 7 (TIRC7) antagonist, preferably an anti-TIRC7 antibody. Particularly useful monoclonal, in particular chimeric anti-TIRC7 antibodies are described. Furthermore, a combination therapy for the treatment of an inflammatory disease, particularly rheumatoid arthritis, is provided involving the use of TIRC7 antagonist, such as anti-TIRC7 antibody in conjunction with an anti-inflammatory drug such as TNF-&#x3b1; antagonist.

Growing community of inventors

Berlin, Germany

Nalan Utku